Colorectal Cancer Prevention (PDQ®): Prevention - Health Professional Information [NCI] - Changes to This Summary (09 / 27 / 2013)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.Editorial changes were made to this summary.This summary is written and maintained by the PDQ Screening and Prevention Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.
Changes to This Summary (06 / 12 / 2013)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.This summary was reformatted.Stage I and Stage II Pancreatic Cancer TreatmentAdded text about a 5-year update of the Radiation Therapy Oncology Group (RTOG)-9704 trial, which reported that patients with pancreatic head tumors had a median survival and 5-year overall survival of 20.5 months and 22% survival rate with gemcitabine, versus 17.1 months and 18% with 5-fluorouracil. Also added text about a secondary analysis of RTOG-9704 that explored the correlation of adherence to protocol-specified radiation with patient outcomes. Added text to state that the European Organization for the Research and Treatment of Cancer/U.S. Gastrointestinal Intergroup (RTOG-0848) phase III adjuvant trial evaluating the impact of chemoradiation after completion of a full course of gemcitabine with or without
AIDS-Related Lymphoma Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Cellular Classification of AIDS-Related Lymphoma
Pathologically, AIDS-related lymphomas are comprised of a narrow spectrum of histologic types consisting almost exclusively of B-cell tumors of aggressive type. These include the following: Diffuse large B-cell lymphoma.B-cell immunoblastic lymphoma.Small noncleaved lymphoma, either Burkitt or Burkitt-like. All three pathologic types are equally distributed and represent aggressive disease.AIDS-related lymphomas, though usually of B-cell origin as demonstrated by immunoglobulin heavy-chain gene rearrangement studies, have also been shown to be oligoclonal and polyclonal as well as monoclonal in origin. Although human immunodeficiency virus (HIV) does not appear to have a direct etiologic role, HIV infection does lead to an altered immunologic milieu. HIV generally infects T lymphocytes whose loss of regulation function leads to hypergammaglobulinemia and polyclonal B-cell hyperplasia. B cells are not the targets of HIV infection. Instead, Epstein-Barr virus (EBV) is thought to be at
Spirituality in Cancer Care (PDQ®): Supportive care - Health Professional Information [NCI] - Relation of Religion and Spirituality to Adjustment, Quality of Life, and Health Indices
Religion and spirituality have been shown to be significantly associated with measures of adjustment and with the management of symptoms in cancer patients. Religious and spiritual coping have been associated with lower levels of patient discomfort as well as reduced hostility, anxiety, and social isolation in cancer patients [1,2,3,4] and in family caregivers. Specific characteristics of strong religious beliefs, including hope, optimism, freedom from regret, and life satisfaction, have also been associated with improved adjustment in individuals diagnosed with cancer.[6,7]Type of religious coping may influence quality of life. In a multi-institutional cross-sectional study of 170 patients with advanced cancer, more use of positive religious coping methods (such as benevolent religious appraisals) was associated with better overall quality of life and higher scores on the existential and support domains of the McGill Quality of Life Questionnaire. In contrast, more use of
Oral Cancer Prevention (PDQ®): Prevention - Patient Information [NCI] - Get More Information From NCI
Call 1-800-4-CANCERFor more information, U.S. residents may call the National Cancer Institute's (NCI's) Cancer Information Service toll-free at 1-800-4-CANCER (1-800-422-6237) Monday through Friday from 8:00 a.m. to 8:00 p.m., Eastern Time. A trained Cancer Information Specialist is available to answer your questions.Chat online The NCI's LiveHelp® online chat service provides Internet users with the ability to chat online with an Information Specialist. The service is available from 8:00 a.m. to 11:00 p.m. Eastern time, Monday through Friday. Information Specialists can help Internet users find information on NCI Web sites and answer questions about cancer. Write to usFor more information from the NCI, please write to this address:NCI Public Inquiries Office9609 Medical Center Dr. Room 2E532 MSC 9760Bethesda, MD 20892-9760Search the NCI Web siteThe NCI Web site provides online access to information on cancer, clinical trials, and other Web sites and organizations that offer support
General Information About Childhood Brain and Spinal Cord Tumors
A childhood brain or spinal cord tumor is a disease in which abnormal cells form in the tissues of the brain or spinal cord. There are many types of childhood brain and spinal cord tumors. The tumors are formed by the abnormal growth of cells and may begin in different areas of the brain or spinal cord. Tumors may be benign (noncancerous) or malignant (cancerous). Together,the brain and ...
Stomach (Gastric) Cancer Screening (PDQ®): Screening - Health Professional Information [NCI] - About This PDQ Summary
Purpose of This SummaryThis PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about stomach (gastric) cancer screening. It is intended as a resource to inform and assist clinicians who care for cancer patients. It does not provide formal guidelines or recommendations for making health care decisions.Reviewers and UpdatesThis summary is reviewed regularly and updated as necessary by the PDQ Screening and Prevention Editorial Board, which is editorially independent of the National Cancer Institute (NCI). The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH). Board members review recently published articles each month to determine whether an article should:be discussed at a meeting,be cited with text, orreplace or update an existing article that is already cited.Changes to the summaries are made through a consensus
Zollinger Ellison syndrome
Important It is possible that the main title of the report Zollinger Ellison Syndrome is not the name you expected. Please check the synonyms listing to find the alternate name(s) and disorder subdivision(s) covered by this report. ...
Childhood Hematopoietic Cell Transplantation (PDQ®): Treatment - Health Professional Information [NCI] - General Information About Hematopoietic Cell Transplantation (HCT)
Rationale for HCTBlood and marrow transplantation (BMT) or HCT is a procedure that involves infusion of cells (hematopoietic stem cells; also called hematopoietic progenitor cells) to reconstitute the hematopoietic system of a patient. The infusion of hematopoietic stem cells generally follows a preparative regimen given to the patient consisting of agents designed to do the following:Create marrow space.Suppress the patient's immune system to prevent rejection.Intensively treat malignant cells in patients with cancer.HCT is currently used in the following three clinical scenarios:Treatment of malignancies.Replacement or modulation of an absent or poorly functioning hematopoietic or immune system.Treatment of genetic diseases in which an insufficient expression of the affected gene product by the patient can be partially or completely overcome by circulating hematopoietic cells transplanted from a donor with normal gene expression.Autologous Versus Allogeneic HCTThe two major
Rectal Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Cellular Classification and Pathology of Rectal Cancer
The World Health Organization (WHO) classification of tumors of the colon and rectum include the following:Epithelial TumorsAdenomaTubular.Villous.Tubulovillous.Serrated.Intraepithelial neoplasia (dysplasia) associated with chronic inflammatory diseasesLow-grade glandular intraepithelial neoplasia.High-grade glandular intraepithelial neoplasia.CarcinomaAdenocarcinoma.Mucinous adenocarcinoma.Signet-ring cell carcinoma.Small cell carcinoma.Adenosquamous carcinoma.Medullary carcinoma.Undifferentiated carcinoma.Carcinoid (well-differentiated neuroendocrine neoplasm)Enterochromaffin (EC)-cell, serotonin-producing neoplasm.L-cell, glucagon-like peptide and pancreatic polypeptide/peptide YY (PYY)-producing tumor.Others.Mixed carcinoma-adenocarcinomaOthers.Nonepithelial TumorsLipoma.Leiomyoma.Gastrointestinal stromal tumor.Leiomyosarcoma.Angiosarcoma.Kaposi sarcoma.Melanoma.Others.Malignant lymphomasMarginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type.Mantle cell